{"id":519,"date":"2022-08-23T13:35:16","date_gmt":"2022-08-23T13:35:16","guid":{"rendered":"http:\/\/clinicalbiochemistry.net\/?page_id=519"},"modified":"2022-08-24T08:05:45","modified_gmt":"2022-08-24T08:05:45","slug":"phd-projects","status":"publish","type":"page","link":"http:\/\/clinicalbiochemistry.net\/?page_id=519","title":{"rendered":"PhD Projects"},"content":{"rendered":"\n

We have a range of self funded PhD projects. Please contact us using the details on the adverts below.<\/p>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/figure>\n\n\n\n

A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease.<\/h2>\n\n\n\n

End-stage Kidney failure, also known as End-stage Kidney Disease (ESKD), is the final, irreversible stage of chronic kidney disease, where kidney function has worsened to the point that the kidneys can no longer function independently. Cardiovascular complications rather than impaired renal function are the leading cause of death in ESKD. This is due to CKD\/ESKD is a chronic systemic proinflammatory state contributing to vascular and myocardial remodelling, atherosclerosis, vascular calcification and senescence, cardiac fibrosis and valve calcification and complex dyslipidaemia. Also, in CKD, due to uraemia, there is disruption of the microbiome and gut barrier function that allows translocation of endotoxin and bacterial metabolites to the systemic circulation, contributing to inflammation and associated cardiovascular disease. In this respect, CKD mimics accelerated ageing of the cardiovascular system. In 2009, an estimated 7,000 extra strokes and 12,000 extra myocardial infarctions per year were due to CKD in the UK, costing the NHS over \u00a3170 million.<\/p>\n\n\n\n

For further information and details on how to apply, please follow link: Link to Project Page<\/span><\/a> <\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

We have a range of self funded PhD projects. Please contact us using the details on the adverts below. A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease. End-stage Kidney failure, also known as End-stage Kidney<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"_links_to":"","_links_to_target":""},"jetpack_shortlink":"https:\/\/wp.me\/P9tPlw-8n","jetpack-related-posts":[{"id":968,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=968","url_meta":{"origin":519,"position":0},"title":"Self-Funded PhD Opportunity: Cardiovascular Disease in ESRD","date":"August 24, 2022","format":false,"excerpt":"A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease. End-stage Kidney failure, also known as End-stage Kidney Disease (ESKD), is the final, irreversible stage of chronic kidney disease, where kidney function has worsened to the point that the kidneys can no longer function independently.\u00a0Cardiovascular complications rather\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2019\/02\/iStock_17432100_MEDIUM.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":549,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=549","url_meta":{"origin":519,"position":1},"title":"PhD Project: BEST Study","date":"January 11, 2019","format":false,"excerpt":"Expediting the confirmation of acute myocardial infarction with point of care troponin and heart fatty acid binding protein testing to facilitate early intervention in emergency department Cardiac troponin is the reference standard biomarker for the diagnosis of acute myocardial infarction (AMI). In the appropriate clinical context, the detection of a\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":99,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=99","url_meta":{"origin":519,"position":2},"title":"Projects","date":"December 17, 2017","format":false,"excerpt":"Details of Current and future projects my be found below. Research underpins specific clinical objectives such as: Generating and validating accurate and timely diagnostics for acute coronary syndromes Improved diagnosis of acute coronary syndromes and heart failure Better management of heart failure, through improved understanding of the underlying patho-physiology Improved\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2017\/12\/Analyser-Pages-300x200.png?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":267,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=267","url_meta":{"origin":519,"position":3},"title":"Cookies Policy","date":"January 2, 2018","format":false,"excerpt":"Cookies policy Introduction 1.1\u00a0\u00a0\u00a0 Our website uses cookies. 1.2\u00a0\u00a0\u00a0 We will ask you to consent to our use of cookies in accordance with the terms of this policy when you first visit our website Credit 2.1\u00a0\u00a0\u00a0 This document was created using a template from SEQ Legal (http:\/\/www.seqlegal.com). \u00a0 About cookies\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":234,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=234","url_meta":{"origin":519,"position":4},"title":"Terms and Conditions","date":"December 27, 2017","format":false,"excerpt":"Terms and conditions of use Introduction 1.1\u00a0\u00a0\u00a0\u00a0 These terms and conditions govern your use of our website. 1.2\u00a0\u00a0\u00a0\u00a0 By using our website, you accept these terms and conditions in full; accordingly, if you disagree with these terms and conditions or any part of these terms and conditions, you must not\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":269,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=269","url_meta":{"origin":519,"position":5},"title":"Privacy Policy","date":"January 2, 2018","format":false,"excerpt":"Privacy policy Introduction 1.1\u00a0\u00a0\u00a0 We are committed to safeguarding the privacy of our website visitors; in this policy we explain how we will handle your personal data. 1.2\u00a0\u00a0\u00a0 We will ask you to consent to our use of cookies in accordance with the terms of this policy when you first\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/519"}],"collection":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=519"}],"version-history":[{"count":12,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/519\/revisions"}],"predecessor-version":[{"id":975,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/519\/revisions\/975"}],"wp:attachment":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}